Chemotherapy for prostate cancer
There have been advances in chemotherapy treatment recently and it is considered for patients with metastatic disease who have failed hormone therapy options. Docetaxel (Taxotere) treatment has been shown to prolong survival in some men with recurrent prostate cancer. The treatment does have side effects, although these are usually limited to hair loss, tiredness and a lowering of the blood count with a risk of infection. A significant proportion of patients with hormone resistant disease, respond (fairly durably) to this type of chemotherapy. Second line chemotherapy is with a drug called mitozantrone. Molecularly based therapies will have an increasing role in the treatment of metastatic prostate cancer. Bupa Cromwell Hospital is at the forefront of this development.